Oncurious NV is a Belgium-based biotech company focusing on the development of innovative oncology treatments.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In Aug 2017, Oncurious acquired a unique portfolio of 5 next-generation preclinical immuno-oncology assets for orphan pediatric oncology indications from venture partner VIB. As part of this agreement, VIB Discovery Sciences will take the lead in the pre-clinical development of these new projects and shall increase its stake in Oncurious, with ThromboGenics remaining the majority shareholder. VIB will also receive a royalty on future sales of any of these assets. ThromboGenics invests an additional 2.1 million in Oncurious.